Drug Shortage Report for POTASSIUM PHOSPHATES INJECTION, USP
| Report ID | 124366 |
| Drug Identification Number | 02139545 |
| Brand name | POTASSIUM PHOSPHATES INJECTION, USP |
| Common or Proper name | Potassium Phosphates Injection |
| Company Name | FRESENIUS KABI CANADA LTD |
| Market Status | MARKETED |
| Active Ingredient(s) | POTASSIUM PHOSPHATE MONOBASIC POTASSIUM PHOSPHATE DIBASIC |
| Strength(s) | 224MG 236MG |
| Dosage form(s) | SOLUTION |
| Route of administration | INTRAVENOUS INTRAVENOUS |
| Packaging size | 50 mL |
| ATC code | B05XA |
| ATC description | I.V. SOLUTION ADDITIVES |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | 2020-11-02 |
| Actual start date | |
| Estimated end date | 2020-12-21 |
| Actual end date | 2021-01-22 |
| Shortage status | Resolved |
| Updated date | 2021-01-26 |
| Company comments | Potassium Phosphates Injection, USP, 3 mmol/mL, Phosphorus SD Vial, 50 mL we will be placing the following products on 50% allocation effective today, Tuesday, September 15, 2020. UPDATE 10/30: Fresenius Kabi Canada Ltd. regrets to advise that due to a production delay, we will be encountering a supply interruption on our Potassium Phosphates Injection, USP, 3 mmol/mL Phosphorous SD Vial 50 mL. Estimated Stockout Date November 2, 2020 Estimated Availability Date December 4, 2020 Our Potassium Phosphates Injection, USP, 3 mmol/mL Phosphorous SD Vial 15 mL vials will be placed on 100% allocation and allocations will be increased to cover the 50 mL demand on a 3:1 ratio (three 15mL vials to one 50mL vial). UPDATE 11/25: We will also be extending the backorder on our Potassium Phosphates Injection, USP 3 mmol/mL Phosphorus SD Vial 50 mL until December 21, 2020. UPDATE We are also pleased to advise that replenishment inventories of our Potassium Phosphates Injection, USP 3 mmol/mL Phosphorus SD Vial 50 mL have been released and the product will be placed on 100% allocation, effective December 22, 2020. Please note that Potassium Phosphates Injection, USP 3 mmol/mL Phosphorus SD Vial 15 mL will remain on 100% allocation. |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 165 GALAXY BLVD, SUITE 100 TORONTO, ONTARIO CANADA M9W 0C8 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v9 | 2021-01-26 | French | Compare |
| v8 | 2021-01-26 | English | Compare |
| v7 | 2020-11-25 | French | Compare |
| v6 | 2020-11-25 | English | Compare |
| v5 | 2020-11-03 | English | Compare |
| v4 | 2020-10-30 | French | Compare |
| v3 | 2020-10-30 | English | Compare |
| v2 | 2020-09-17 | French | Compare |
| v1 | 2020-09-17 | English | Compare |
Showing 1 to 9 of 9